






Figure 2

TCR
HA2-MJ1-DP57
HA2-MJ1-DP2
HA2-MJ1-DP37
HA2-MJ2-DP9
HA2-MJ2-DP25
HA2-MJ7-DP19
HA2-MJ3-DP12
HA2-MJ2-DP17
HA2-MJ2-DP8
HA2-BG3-DP67
HA2-BG3-DP42
HA2-BG3-DP15
HA2-MJ1-DP33
HA2-MJ3-DP20
HA2-MJ2-DP1





Gated on Live TCR+ cells

Figure 4B






Figure 4C

DEL (High HA-2 / High MHC)



THP-1 (Low HA-2 / Medium MHC)






Figure 4D






Figure 4D (cont.)








Figure 6

TCR
HA2-MJ7-DP19
HA2-MJ14-SP4
HA2-MJ2-DP8
HA2-MJ13-DP148
HA2-MJ14-DP317
HA2-MJ2-DP22
HA2-MJ14-DP331
HA2-MJ14-DP45
HA2-MJ2-DP24
HA2-MJ14-DP162
HA2-MJ14-DP137
HA2-MJ14-DP33
HA2-MJ9-DP5
HA2-MJ13-SP43
HA2-MJ13-DP32








Figure 7D




Figure 7E






Figure 7G

THP-1 (Low HA-2 / Medium MHC)








Figure 7J




Figure 7K

NB4 (E:T 10:1)
Irrelevant MHC




Figure 7L




Figure 7M

NB4 (Irrelevant MHC)





Figure 8A






Figure 8C






Figure 8D










Figure 8G










Figure 8J









Figure 8M






Figure 10A




Figure 10B




Figure 11A




Figure 11B

Peptide	EC ₅₀ (pg/mL)	R ²
HA-2 ⁺	17.06	0.997
HA-2 ⁻	251.50	0.991
MYO3A/B	2,450	0.997
MALT1	62,160	0.998
KLHL30	n/a	n/a
MTA1	n/a	n/a
HUWE1	n/a	n/a

Figure 12A




Figure 12B




Figure 13





Figure 13 (cont.)



A

Pol-2 Antibody

CD24 (CD86+132)



TSC-101

HA2-7-DP19

HA2-14-DP137

HA2-14-SP4

NTD



Pan T cells contained evidence of CD8⁺ and CD8⁻ T cells) were transduced by antisense MAb-2-specific TCRα and assessed for lineage-specific responses to PMA and IL-2. (A) Representative histograms of intracellular expression of TCR-β in CD8⁺ (B) and CD8⁻ T-regulated CD8α (CD8α+T0). (C) TCR-101 shows staining cytoplasmically in MAb-2 cancer cell line DEL. (D-E) CD8α+T0 (CD8α+T0⁺) and CD8α⁻T0 (CD8α⁻T0⁺) populations. F-H TCR-101 staining in CD8α+T0 (F), CD8α⁻T0 (G), and CD8α⁻T0 (H) cultures. MAb-2-specific CD8⁺ and CD8⁻ T cell proliferation shown as co-cultured with MAb-2 THP-1 cells. Histograms show dilution of CFSE trace (not to scale) used to label T cells. (I) TCR-101 efficiently locates cytokines when co-cultured with THP-1 cells. Different MAb-2 specific TCRs were compared by one-way ANOVA. * indicates significant difference between parameters, based on which each TCR was attributed to every other TCR. Differences that were non-significant (*n.s.*) are grouped; all other differences were significant with P<0.05. Data are representative of 2–3 unique cultures.

Figure 13 (cont.)

